Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 1045-1052

  Hamaguchi, Yasuhito ^a   Kodera, Masanari ^b   Matsushita, Takashi ^a   Hasegawa, Minoru ^a   Inaba, Yuki ^b   Usuda, Toshikazu ^b   Kuwana, Masataka ^c   Takehara, Kazuhiko ^a   Fujimoto, Manabu ^a,d  

^a KANAZAWA UNIVERSITY   (Japan)

^b CHUKYO HOSPITAL   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III ANTIBODY; UNCLASSIFIED DRUG; DNA DIRECTED RNA POLYMERASE III;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; JAPANESE (PEOPLE); KIDNEY DISEASE; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCLERODERMA; SCLERODERMA RENAL CRISIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; AGED; BLOOD; DISEASE COURSE; IMMUNOLOGY; JAPAN;

ADULT; AGED; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84925710188     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38994     Document Type: Article

References (33)

1. Tan EM,. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44: 93-151.
2. Okano Y,. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709-35.
3. Denton CP,. Renal manifestations of systemic sclerosis-clinical features and outcome assessment. Rheumatology (Oxford) 2008; 47: 54-6.
4. Steen VD, Medsger TA Jr, Osial TA Jr, Ziegler GL, Shapiro AP, Rodnan GP,. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-86.
5. Steen VD, Medsger TA Jr., Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000; 133: 600-3.
6. Teixeira L, Mahr A, Berezne A, Noel LH, Guillevin L, Mouthon L,. Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007; 1108: 249-58.
7. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L,. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-95.
8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
9. LeRoy EC, Medsger TA Jr., Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
10. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
11. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
12. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD, et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007; 56: 2740-6.
13. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M,. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 75-83.
14. Steen VD,. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
15. Fertig N, Domsic RT, Rodriguez-Reyna T, Kuwana M, Lucas M, Medsger TA Jr, et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61: 958-65.
16. Koschik RW II, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr., Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012; 30: 12-6.
17. Kaji K, Fertig N, Medsger TA Jr, Satoh T, Hoshino K, Hamaguchi Y, et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res (Hoboken) 2014; 66: 575-84.
18. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr., Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005; 52: 2425-32.
19. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, et al. Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology (Oxford) 2009; 48: 1570-4.
20. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147: 391-8.
21. Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome: specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 1994; 94: 1981-9.
22. Harvey GR, Rands AL, McHugh NJ,. Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II. Clin Exp Immunol 1996; 105: 468-74.
23. Okano Y, Steen VD, Medsger TA Jr., Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119: 1005-13.
24. Kuwana M, Kaburaki J, Mimori T, Tojo T, Homma M,. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis. J Clin Invest 1993; 91: 1399-404.
25. Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr., Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007; 34: 104-9.
26. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
27. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43: 2445-54.
28. Steen VD,. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315-33.
29. Nguyen B, Mayes MD, Arnett FC, del Junco D, Reveille JD, Gonzalez EB, et al. HLA-DRB1 0407 and 1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63: 530-4.
30. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ,. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999; 117: 395-402.
31. Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton CP,. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1218-21.
32. Steen VD, Medsger TA Jr., Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-9.
33. Helfrich DJ, Banner B, Steen VD, Medsger TA Jr., Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32: 1128-34.